
🔴 $REPL -19.5% — Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
━━━━━━━━━━━━━━━━━━━━
📰 Replimune Group, Inc., a biotechnology company based in Woburn, Massachusetts, announced on April 10, 2026, that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for RP1 combined with nivolumab for treating advanced melanoma. The company disagrees with the FDA's assessment that the data supporting the application is insufficient, despite the IGNYTE trial showing a 34% response rate and a median duratio
✅ Positives
• Patients in the IGNYTE trial showed a median progression-free survival of 30.6 months with RP1 plus nivolumab.
• The IGNYTE trial demonstrated a 34% response rate in patients with advanced melanoma who had progressed on prior anti-PD-1 therapy.
• Replimune's data indicated a favorable safety profile for RP1 combined with nivolumab.
⚠️ Risks
• The FDA issued a CRL citing concerns over tumor assessment methodology and review process inconsistencies.
• The company faced challenges due to a new review team that did not meet with them during the resubmission process.
• Regulatory delays have led to job cuts and scaling back of manufacturing operations, impacting the company's development efforts.
🤖 AI Impact: 4/5 High
💲 $4.76 (-19.5%) | Vol: 2.9M | MCap: 393M | Float: 76.6M (x0.04)
📊 app.ticker.guru/article?id=944…
#stocks #FDA #pennystocks
English